# Annexon, Inc.: financial statements, quarterly

ANNX · Nasdaq · CIK 1528115 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/annx.md) · [Financials](/companies/annx/financials.md) · [Filings](/companies/annx/filings.md) · [Insiders](/companies/annx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/annx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [27.9](/filings/0000950170-24-127057.md) | [23.3 d](/filings/0000950170-25-030849.md) | [21.0](/filings/0000950170-25-069200.md) | [25.0](/filings/0000950170-25-108869.md) | [30.1](/filings/0001193125-25-274240.md) | [43.4 d](/filings/0001193125-26-131782.md) | [48.2](/filings/0001193125-26-211931.md) | [44.2](/filings/0001193125-26-346779.md) | [49.7](/filings/0001193125-25-274240.md) | [42.7 d](/filings/0001193125-26-131782.md) | [35.8](/filings/0001193125-26-211931.md) | [46.6](/filings/0001193125-26-346779.md) |
| Operating income | $m | [(34.8)](/filings/0000950170-24-127057.md) | [(30.0) d](/filings/0000950170-25-030849.md) | [(28.6)](/filings/0000950170-25-069200.md) | [(33.6)](/filings/0000950170-25-108869.md) | [(39.4)](/filings/0001193125-25-274240.md) | [(52.5) d](/filings/0001193125-26-131782.md) | [(57.4)](/filings/0001193125-26-211931.md) | [(51.7)](/filings/0001193125-26-346779.md) | [(57.0)](/filings/0001193125-25-274240.md) | [(50.3) d](/filings/0001193125-26-131782.md) | [(46.1)](/filings/0001193125-26-211931.md) | [(57.2)](/filings/0001193125-26-346779.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(32.5)](/filings/0000950170-24-127057.md) | [(27.9) d](/filings/0000950170-25-030849.md) | [(25.2)](/filings/0001193125-25-274240.md) | [(29.6)](/filings/0001193125-25-274240.md) | [(34.8)](/filings/0001193125-25-274240.md) | [(48.6) d](/filings/0001193125-26-131782.md) | [(54.4)](/filings/0001193125-26-346779.md) | [(49.2)](/filings/0001193125-26-346779.md) | [(54.9)](/filings/0001193125-25-274240.md) | [(48.3) d](/filings/0001193125-26-131782.md) | [(44.1)](/filings/0001193125-26-346779.md) | [(55.3)](/filings/0001193125-26-346779.md) |
| Diluted EPS | $ per share | [(0.43)](/filings/0000950170-24-127057.md) | not reported | [(0.21)](/filings/0000950170-25-069200.md) | [(0.23)](/filings/0000950170-25-108869.md) | [(0.25)](/filings/0001193125-25-274240.md) | not reported | [(0.37)](/filings/0001193125-26-211931.md) | [(0.34)](/filings/0001193125-26-346779.md) | [(0.37)](/filings/0001193125-25-274240.md) | not reported | [(0.23)](/filings/0001193125-26-211931.md) | [(0.28)](/filings/0001193125-26-346779.md) |
| Basic EPS | $ per share | [(0.43)](/filings/0000950170-24-127057.md) | not reported | [(0.21)](/filings/0000950170-25-069200.md) | [(0.23)](/filings/0000950170-25-108869.md) | [(0.25)](/filings/0001193125-25-274240.md) | not reported | [(0.37)](/filings/0001193125-26-211931.md) | [(0.34)](/filings/0001193125-26-346779.md) | [(0.37)](/filings/0001193125-25-274240.md) | not reported | [(0.23)](/filings/0001193125-26-211931.md) | [(0.28)](/filings/0001193125-26-346779.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [133](/filings/0000950170-23-062913.md) | [225](/filings/0000950170-25-030849.md) | [152](/filings/0000950170-24-058659.md) | [157](/filings/0000950170-24-095401.md) | [79.5](/filings/0000950170-24-127057.md) | [49.5](/filings/0001193125-26-131782.md) | [97.1](/filings/0000950170-25-069200.md) | [132](/filings/0000950170-25-108869.md) | [139](/filings/0001193125-25-274240.md) | [162](/filings/0001193125-26-346779.md) | [175](/filings/0001193125-26-211931.md) | [199](/filings/0001193125-26-346779.md) |
| Current assets | $m | [169](/filings/0000950170-23-062913.md) | [264](/filings/0000950170-25-030849.md) | [271](/filings/0000950170-24-058659.md) | [374](/filings/0000950170-24-095401.md) | [344](/filings/0000950170-24-127057.md) | [316](/filings/0001193125-26-131782.md) | [268](/filings/0000950170-25-069200.md) | [231](/filings/0000950170-25-108869.md) | [193](/filings/0001193125-25-274240.md) | [242](/filings/0001193125-26-346779.md) | [228](/filings/0001193125-26-211931.md) | [213](/filings/0001193125-26-346779.md) |
| Total assets | $m | [204](/filings/0000950170-23-062913.md) | [298](/filings/0000950170-25-030849.md) | [304](/filings/0000950170-24-058659.md) | [406](/filings/0000950170-24-095401.md) | [379](/filings/0000950170-24-127057.md) | [350](/filings/0001193125-26-131782.md) | [303](/filings/0000950170-25-069200.md) | [265](/filings/0000950170-25-108869.md) | [229](/filings/0001193125-25-274240.md) | [278](/filings/0001193125-26-346779.md) | [263](/filings/0001193125-26-211931.md) | [246](/filings/0001193125-26-346779.md) |
| Current liabilities | $m | [17.2](/filings/0000950170-23-062913.md) | [17.9](/filings/0000950170-25-030849.md) | [13.1](/filings/0000950170-24-058659.md) | [17.1](/filings/0000950170-24-095401.md) | [20.0](/filings/0000950170-24-127057.md) | [30.5](/filings/0001193125-26-131782.md) | [33.5](/filings/0000950170-25-069200.md) | [40.6](/filings/0000950170-25-108869.md) | [43.6](/filings/0001193125-25-274240.md) | [42.6](/filings/0001193125-26-346779.md) | [35.9](/filings/0001193125-26-211931.md) | [38.5](/filings/0001193125-26-346779.md) |
| Total liabilities | $m | [47.0](/filings/0000950170-23-062913.md) | [47.1](/filings/0000950170-25-030849.md) | [41.7](/filings/0000950170-24-058659.md) | [45.0](/filings/0000950170-24-095401.md) | [47.2](/filings/0000950170-24-127057.md) | [57.0](/filings/0001193125-26-131782.md) | [59.2](/filings/0000950170-25-069200.md) | [65.6](/filings/0000950170-25-108869.md) | [67.7](/filings/0001193125-25-274240.md) | [65.9](/filings/0001193125-26-346779.md) | [58.4](/filings/0001193125-26-211931.md) | [60.0](/filings/0001193125-26-346779.md) |
| Shareholders' equity | $m | [157](/filings/0000950170-24-127057.md) | [251](/filings/0001193125-26-131782.md) | [262](/filings/0001193125-25-274240.md) | [361](/filings/0001193125-25-274240.md) | [332](/filings/0001193125-25-274240.md) | [293](/filings/0001193125-26-346779.md) | [244](/filings/0001193125-26-346779.md) | [199](/filings/0001193125-26-346779.md) | [161](/filings/0001193125-25-274240.md) | [212](/filings/0001193125-26-346779.md) | [205](/filings/0001193125-26-346779.md) | [186](/filings/0001193125-26-346779.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(28.3) d](/filings/0000950170-24-127057.md) | [(23.5) d](/filings/0000950170-25-030849.md) | [(28.3)](/filings/0000950170-25-069200.md) | [(21.7) d](/filings/0000950170-25-108869.md) | [(32.0) d](/filings/0001193125-25-274240.md) | [(36.0) d](/filings/0001193125-26-131782.md) | [(50.1)](/filings/0001193125-26-211931.md) | [(38.1) d](/filings/0001193125-26-346779.md) | [(52.3) d](/filings/0001193125-25-274240.md) | [(45.9) d](/filings/0001193125-26-131782.md) | [(46.8)](/filings/0001193125-26-211931.md) | [(48.0) d](/filings/0001193125-26-346779.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-127057.md) | [0.0 d](/filings/0000950170-25-030849.md) | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-131782.md) | [0.1](/filings/0001193125-26-211931.md) | [0.0 d](/filings/0001193125-26-346779.md) | [0.0 d](/filings/0001193125-25-274240.md) | [0.0 d](/filings/0001193125-26-131782.md) | [0.0](/filings/0001193125-26-211931.md) | [0.1 d](/filings/0001193125-26-346779.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q3 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [68.7](/filings/0000950170-23-062913.md) | [73.9](/filings/0000950170-24-058659.md) | [75.2](/filings/0000950170-24-095401.md) | [75.3](/filings/0000950170-24-127057.md) | [123](/filings/0000950170-25-069200.md) | [130](/filings/0000950170-25-108869.md) | [140](/filings/0001193125-25-274240.md) | [148](/filings/0001193125-26-211931.md) | [148](/filings/0001193125-26-346779.md) | [149](/filings/0001193125-25-274240.md) | [194](/filings/0001193125-26-211931.md) | [201](/filings/0001193125-26-346779.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 38,563,565 at 2022-05-02, from the cover of the [10-Q filed 2022-05-09](/filings/0000950170-22-008494.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.